Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
USL261 intranasal midazolam versus placebo for intermittent increased seizure activity in the epilepsy monitoring unit
2014-003961-49Phase 3Completed
- Sponsor
- Upsher-Smith Laboratories
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of midazolam in epilepsy (2 arms), sponsored by Upsher-Smith Laboratories. Primary endpoint: Proportion of subjects seizure-free during the treatment phase. Started Nov 2014; status: completed.
02
Drugs
midazolam
03
Conditions
epilepsy
Beyond the preview
Go deeper on 2014-003961-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003961-49.